To validate DeepRSMA’s ability to predict RNA–small molecule affinity with reasonable accuracy, we applied DeepRSMA to predict the binding affinity of SMN2 pre-mRNA and two small molecules with therapeutic potential for SMA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.